"Pharmaceutical leader" overseas pharmaceutical enterprises inspection summary a batch of drugs were named for key monitoring
-
Last Update: 2020-01-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
(2020 / 01 / 16) inventory of listing, financing and M & A in the field of biomedicine in 2019; Boao Lecheng released the latest operation data to merge health care and drug regulatory agencies; from the perspective of changes in bidding rules, the attitude of regulators towards national centralized procurement; 2017-2019 inspection of overseas pharmaceutical enterprises by the State Food and Drug Administration A new batch of drugs will be included in the scope of key monitoring The effect of acceleration is almost immediate What do these changes mean? Treat both inside and outside equally Fujian comes first again Only one international product of the same variety is listed in the United States.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
